Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America, July 2022 JPGN

Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America, July 2022 JPGN

Key:

Complete
Failed
Available
Locked
CME Requirements and Learning Objectives: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America, July 2022 JPGN
Open to download resource.
Open to download resource.
You must register to access.
Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
Open to download resource.
Open to download resource.
You must register to access.
Post-Test: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
3 Questions  |  Unlimited attempts  |  2/3 points to pass
3 Questions  |  Unlimited attempts  |  2/3 points to pass
You must register to access.
Post-Webinar Evaluation: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
14 Questions
14 Questions Post-Webinar Evaluation: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
You must register to access.
Certificate: Utilization of anti-tumor necrosis factor biologics in Very Early Onset Inflammatory Bowel Disease (VEOIBD): a multicenter retrospective cohort study from North America
1.00 credit  |  Certificate available
1.00 credit  |  Certificate available
You must register to access.